Krystal Biotech, Inc. (KRYS) Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of Vyjuvek for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB)
Dystrophic epidermolysis bullosa is a genetic disorder affecting the skin and other organs.
Final decision by the European Commission is expected in the second quarter of 2025.
The CHMP positive opinion was based on results from Phase 1/2 GEM-1 and Phase 3 GEM-3 studies, which provided clear evidence of durable wound closure following administration of Vyjuvek.
Vyjuvek, a topical gene therapy, is already approved by the FDA for the treatment of wounds in patients with DEB.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.